# A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

> **NCT06471205** · PHASE2 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 52 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** BL-B01D1
- **DRUG:** PD-1 Monoclonal Antibody

## Key facts

- **NCT ID:** NCT06471205
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-02
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06471205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06471205, "A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06471205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*